Latest Caris Life Sciences Stories
Five Separate Research Presentations Offer Data on the Possible Future Application of Circulating Microvesicles to Cancer Care IRVING, Texas, April 16, 2013 /PRNewswire/ -- Caris Life Sciences(TM), a leading biosciences company focused on fulfilling the promise of personalized medicine, today announced that five data presentations related to blood-based circulating microvesicles (cMVs) will be presented this week at the 2013 International Society for Extracellular Vesicles (ISEV)...
March 10 Event at SGO Annual Meeting to Feature Presentations by Noted Experts in Gynecologic Oncology and Molecular Genetics IRVING, Texas, March 8, 2013 /PRNewswire/ -- Caris Life Sciences(TM), a leading biosciences company focused on fulfilling the promise of personalized medicine, will sponsor an expert symposium, Integrating Next Generation Sequencing Into the Clinical Management of Gynecologic Cancers, at the 2013 Society of Gynecologic Oncology (SGO) Annual Meeting on Women's...
Role will help further advance revolutionary blood-based technology IRVING, Texas, March 5, 2013 /PRNewswire/ -- Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of personalized medicine, announced today that it has named Joachim Schorr, PhD, as its Chief Scientific Officer. He joins Caris in this role after working as a consultant with the company during the past year. In this expanded capacity, Dr. Schorr's extensive expertise in the molecular...
IRVING, Texas, Jan. 28, 2013 /PRNewswire/ -- Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of personalized medicine, announced today the commercial availability of mutational analysis by Next-Generation Sequencing (NGS), which will replace its former mutational analysis platform. NGS joins an extensive collection of tumor profiling technologies currently employed by Caris Molecular Intelligence(TM) Service (MI Profile(TM)), including...
IRVING, Texas, Dec. 5, 2012 /PRNewswire/ -- Caris Life Sciences, a leading biosciences company focused on enabling precise and personalized healthcare through molecular profiling and blood-based diagnostic services, announces its sponsorship and support of the CancerCare Connect Education Workshop entitled, "Understanding the Molecular Portrait of Breast Cancer," December 14, 2012, 1:30 pm - 2:30 pm , ET at www.cancercare.org/connect_workshops. The patient-focused workshop...
IRVING, Texas, Nov. 12, 2012 /PRNewswire/ -- Caris Life Sciences(TM), a leading biosciences company focused on enabling personalized healthcare through molecular profiling and blood-based diagnostic services, has added ROS1 and MGMT-Methylation to the company's evidence-based molecular profiling service. The company is one of only a few entities that offer both of these tests commercially. These markers are believed to serve as clinically-important aids in the development of...
IRVING, Texas, June 26, 2012 /PRNewswire/-- Caris Life Sciences(®), a leading biosciences company focused on enabling precise and personalized healthcare through molecular profiling and blood-based diagnostic services, today announced the launch of Caris Target Now(TM) Select, an advanced, evidence-based molecular profiling service for patients with non-small cell lung cancer (NSCLC), melanoma, and cancers of the breast, colon and ovary. In addition, the company has enhanced the...
CHICAGO, June 4, 2012 /PRNewswire/ -- Caris Life Sciences announced today that two data presentations underscore the importance of molecular profiling in patients with pancreatic cancer and uveal melanoma, with several potentially promising therapeutic targets identified in both diseases. The two datasets, both of which were assembled using the company's Caris Target Now(TM) evidence-based molecular profiling service, were presented here today at the 2012 annual meeting of the...
IRVING, Texas, June 3, 2012 /PRNewswire/ -- Caris Life Sciences(®), a leading biosciences company focused on enabling precise and personalized healthcare through molecular profiling and blood-based diagnostic services, announces the upcoming introduction of Caris Target Now Select((TM)), an advanced, evidence-based molecular profiling service for patients with cancers of the breast, colon, and ovary, non-small cell lung cancer (NSCLC), and melanoma. The new service...
CHICAGO, June 2, 2012 /PRNewswire/ -- -- TLE3 Biomarker Over-expressed in HER2-positive, Hormone Receptor-positive, and Triple-negative Breast Cancers -- -- EGFR status May Facilitate Therapeutic Decision-making in Head and Neck Cancer -- Caris Life Sciences announced today the utility of the company's Caris Target Now(TM) evidence-based molecular profiling service in the characterization of breast and head and neck cancers. These data were presented today at the...
